Carisma Therapeutics (CARM) Stock Analysis & Winston Score

Carisma Therapeutics is a small biotech company working on new cancer treatments. Instead of using the more common T-cell approach, Carisma engineers a different type of immune cell called a macrophage to find and attack tumors. Its main focus is on developing CAR-M (chimeric antigen receptor macrophage) therapies, which are designed for patients with solid tumor cancers who have few other options. The company earns most of its revenue from research grants and partnerships rather than product sales, since it has no approved drugs on the market yet. Carisma operates primarily in the United States and is a very early-stage company, meaning it spends far more money than it brings in — which explains the deeply negative return on invested capital. Its main edge is its proprietary macrophage platform, which is a less crowded space than T-cell therapies, but the biggest risk is that clinical trials could fail, and the company may need to raise more cash to keep operating.